€ 8.4 bn
Q1/2016: €7.0 bn
€ 1560 m
Q1/2016: €1.241 m
€ 1216 m
Q1/2016: €959 m
Dec. 31, 2016: 232,873
€ 457 m
Q1/2016: €358 m
Earnings per Share2
1 In constant currency
2 Net income attributable to shareholders of Fresenius SE & Co. KGaA
Fresenius Helios is investing more than €18 million to expand the company’s hospital in the German town of Bad Saarow, about 25 kilometers (15 miles) east of Berlin. The project at HELIOS Hospital Bad Saarow includes construction of a new building that will add bed capacity to meet growing demand, and an expansion of the radiology department. The construction is scheduled for completion in spring 2019.
Fresenius was presented yesterday with the Corporate Finance Award for the company's acquisition of Quirónsalud, Spain’s largest private hospital operator. The award is given annually by the major German business daily Börsen-Zeitung for transactions judged to be outstanding in both strategical and financial terms. Fresenius won in the Large Caps category, which groups major companies. With the Quirónsalud acquisition, the Börsen-Zeitung said, “Fresenius succeeded in making a quantum leap in the hospital business."
Azacitidine, a nucleoside metabolic inhibitor, expands the company's sterile injectable portfolio in oncology.
Vecuronium Bromide, a neuromuscular blocker, expands the company's sterile injectable portfolio in anesthesia.
HELIOS Hospital Wesermarsch has gone into operation in a newly built facility in the northern German town of Nordenham. The new hospital building has 120 patient beds, three operating rooms and a hybrid cardiac catheterization lab. Capacity can be increased to 235 beds, if needed. Fresenius Helios invested €36 million in the facility, which took about three years to build, with the County of Wesermarsch contributing an additional €10 million.
Clofarabine, a pediatric cancer product, expands the company's sterile injectable portfolio in oncology.
Following Fresenius’ announcement to acquire Akorn, Inc. and Merck KGaA’s biosimilars business, the rating agencies Standard & Poor’s (BBB-, stable), Moody’s (Baa3, stable) and Fitch (BBB-, stable) confirm the corporate credit ratings of Fresenius to be unaffected.
Fresenius Kabi USA has won the prestigious 2016 Pharmaceutical Supplier of the Year Award from Vizient Inc., the largest group purchasing organization for U.S. academic medical centers, community hospitals, pediatric facilities, integrated health delivery networks and non-acute health care providers. Fresenius Kabi has won six Vizient awards for service excellence in recent years.
Fresenius Vamed will realize a 350-bed building at University Hospital St. Pölten, in Austria. Working with a partner company, Fresenius Vamed will be the general contractor on the €176 million project. The new building will have some 21,000 square meters (226,000 square feet) of floor space, housing a range of specialist wards. Construction is scheduled to begin in 2019.
Fresenius Helios is investing €14 million to modernize its hospital in Wipperfürth, North Rhine-Westphalia. Starting late this month, two wards will be completely renovated and expanded, with three delivery rooms to follow. To minimize disruptions to hospital operations, the individual renovations are being carried out in sequence. When completed in early 2019, they will provide more comfort for patients and reduce the distances that need to be walked inside the hospital.
Fitch Ratings has assigned Fresenius Finance Ireland’s €2,600 million notes issued to finance the acquisition of Quirónsalud an instrument rating of BBB-. It also affirmed Fresenius’ corporate credit rating at BBB-. The outlook is stable. The €2,600 million notes were drawn under the newly established Fresenius European Medium Term Note (EMTN) Program and issued by Fresenius Finance Ireland plc., a wholly owned subsidiary of Fresenius SE & Co. KGaA.
Fresenius Helios has opened the new building at its hospital in the western German city of Duisburg. The 22,000-square-meter (237,000-square-foot) structure will accommodate up to 350 inpatients. Construction took two years, with Fresenius Helios investing €50 million in the new building. The move from the existing facility into the new building will start later this month.
Quirónsalud, a unit of Fresenius Helios, is investing about €40 million to build a proton beam therapy center in Madrid. Scheduled for opening in 2019, it will be the first facility of this type for treating cancer patients in Spain. Currently, every patient who can benefit from proton beam therapy must seek treatment outside the country. In proton beam therapy, the use of a high-energy beam allows tumors to be irradiated with lower total doses of radiation and reduced exposure to surrounding tissue compared with conventional radiation therapy. Quirónsalud will also modernize and expand its radiotherapy clinics in Palmaplanas (Mallorca) and Seville.
Dilaudid (HYDROmorphone HCl injection) is now available in the company’s Simplist™ ready-to-administer prefilled syringe in the United States. This marks the third product launch for the Simplist™ line following ownership by Fresenius Kabi.
Fresenius successfully placed €1.0 billion of Schuldschein Loans. Given the substantial investor demand, the volume of the issuance was significantly upsized. The Schuldschein Loans were issued in tranches of five, seven and ten years with fixed and variable interest rates. The proceeds will be used general corporate purposes and the acquisition of Quirónsalud. Funding of the transaction will be on January 31, 2017. More than 230 investors participated. The placement was arranged by Bayerische Landesbank, Deutsche Bank AG, DZ BANK and NORD/LB Norddeutsche Landesbank Girozentrale.
Heparin Sodium, an anticoagulent, is now available in the company’s Simplist™ ready-to-administer prefilled syringe in the United States. This marks the second new product launch for the Simplist™ line following ownership by Fresenius Kabi. The launch expands Fresenius Kabi’s overall Heparin portfolio.
CATSmart is Fresenius Kabi’s next-generation continuous autotransfusion system, which helps reduce blood loss during surgery. CATSmart will be distributed in the U.S. by Terumo Cardiovascular Group. Fresenius Kabi USA and Terumo Cardiovascular Group have signed an exclusive, five-year distribution agreement for CATSmart.
Tigecycline, an antibiotic, expands Fresenius Kabi's anti-infective portfolio.
Investor Relations General Presentation (PDF, 840 KB)
Quarterly Financial Report Q1 2017 (IFRS) (PDF, 295 KB)
Fresenius Factsheet Q1/2017 (PDF, 458 KB)
Annual Report 2016 (U.S. GAAP) (PDF, 2.89 MB)
Consolidated Financial Statements / Management Report 2016 (IFRS) (PDF, 1.02 MB)
Financial Statements 2016 (HGB) (PDF, 571 KB)
Quarterly Financial Report Q3 2016 (IFRS) (PDF, 373 KB)
Quarterly Financial Report Q3 2016 (US-GAAP) (PDF, 337 KB)
Quarterly Financial Report Q2 2016 (IFRS) (PDF, 333 KB)
Quarterly Financial Report Q2 2016 (US-GAAP) (PDF, 369 KB)
Quarterly Financial Report Q1 2016 (IFRS) (PDF, 309 KB)
Quarterly Financial Report Q1 2016 (US-GAAP) (PDF, 830 KB)
Quarterly Financial Report Q3 2015 (US-GAAP) (PDF, 327 KB)
Quarterly Financial Report Q2 2015 (US-GAAP) (PDF, 375 KB)
Quarterly Financial Report Q3 2014 (US-GAAP) (PDF, 400 KB)
Quarterly Financial Report Q1 2015 (US-GAAP) (PDF, 317 KB)
Annual Report 2014 (US-GAAP) (PDF, 3.04 MB)